STUDY ON THE IMPACTS OF CHEMOTHERAPY ON THE HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS OF BREAST CANCER PATIENTS AT CAN THO CITY ONCOLOGY HOSPITAL
Main Article Content
Abstract
Background: Chemotherapy is the method of choice after surgery, bringing maximum effectiveness in treating breast cancer. Information on the rate and degree of toxicity on the hematological system, liver, kidney help clinicians to provide comprehensive care for patients. Objectives: To determine the rate and degree of toxicities on the hematopoietic system, liver kidney of breast cancer patients after chemotherapy at Can Tho Oncology Hospital. Materials and methods: Descriptive cross-sectional study. Subjects are breast cancer patients who have undergone surgery and chemotherapy. Late-stage cases will not be included in the study. Results:
125 cases were selected. The patient’age were 50-59 years old, tumor in the upper outer quadrant, adenocarcinoma NST grade 2 and stage IIA, IIB. The prevalence of toxicity on the hematological system, liver, and kidney includes decreased hemoglobin (64%), leukopenia (8%), neutropenia (15.2%), thrombocytopenia ( 2.4%), increased blood creatinine (0.8%), increased AST, ALT (19.2% and 27.25%, respectively). The majority of toxicity cases are grade I, grade II. The highest degree of toxicity was grade III leukopenia (0.8%) and grade III and IV neutropenia (2.4% and 0.8%, respectively). Conclusions: The most common hematological toxicity is a mild decrease in hemoglobin. Toxicity causing leukopenia, neutropenia is common, can be grade III, IV. Hepatotoxicity is common in grade I, grade II, whereas nephrotoxicity is extremly rare.
Article Details
Keywords
chemotherapy, breast cancer, treatment-related effects, myelosuppression, metabolic dysfunction
References
2. Wondimneh B., Setty S. A. D., Asfeha G. G., Belay E., Gebremeskel G., et al. Comparison of Hematological and Biochemical Profile Changes in Pre- and Post-Chemotherapy Treatment of Cancer Patients Attended at Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia 2019: A Retrospective Cohort Study. Cancer Manag Res. 2021. 13, 625-632, DOI: 10.2147/CMAR.S274821.
3. Trần Nguyên Hà, Phan Thị Hồng Đức, Lê Thị Hồng Vân. Đánh giá kết quả hóa trị hỗ trợ kết hợp trastuzumab trong ung thư vú giai đoạn I, II, III có biểu hiện quá mức HER2. Tạp chí Ung thư học Việt Nam, 2019. 5, 459-469.
4. Võ Văn Phương, Nguyễn Văn Khoa, Trần Thị Thanh Hoa. Đánh giá kết quả hóa trị bổ trợ phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn II, IIIA hạch nách dương tính tại bệnh viện đa khoa tỉnh Hà Tĩnh. Tạp chí Y học lâm sàng. 2020. 65, 36-42.
5. Nguyễn Hoàng Gia, Lê Thu Hà, Hán Thị Bích Hợp. Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T liều mau trên bệnh nhân ung thư vú giai đoạn III. Tạp chí Ung thư học Việt Nam. 2018. 4, 393-400.
6. Vương Đình Thy Hảo, Nguyễn Ngọc Bảo Hoàng, Nguyễn Thị Thu Hằng, Nguyễn Tiến Dũng, Nguyễn Thị Thanh Mai và cộng sự. Pegfilgrastim dự phòng nguyên phát sốt giảm bạch cầu sau hóa trị ung thư vú phác đồ docetaxel, doxorubicin, cyclophosphamide. Tạp chí y học lâm sàng. 2018. 50, 109-116.